ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

OPTI Optibiotix Health Plc

20.25
-0.75 (-3.57%)
Last Updated: 11:52:41
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Optibiotix Health Plc LSE:OPTI London Ordinary Share GB00BP0RTP38 ORD 2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.75 -3.57% 20.25 20.00 20.50 21.50 20.25 21.00 403,566 11:52:41
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Noncomml Resh Organizations 457k 2.59M 0.0284 7.31 18.92M
Optibiotix Health Plc is listed in the Noncomml Resh Organizations sector of the London Stock Exchange with ticker OPTI. The last closing price for Optibiotix Health was 21p. Over the last year, Optibiotix Health shares have traded in a share price range of 5.75p to 43.50p.

Optibiotix Health currently has 91,190,661 shares in issue. The market capitalisation of Optibiotix Health is £18.92 million. Optibiotix Health has a price to earnings ratio (PE ratio) of 7.31.

Optibiotix Health Share Discussion Threads

Showing 26926 to 26948 of 147425 messages
Chat Pages: Latest  1085  1084  1083  1082  1081  1080  1079  1078  1077  1076  1075  1074  Older
DateSubjectAuthorDiscuss
26/7/2017
08:14
I notice STBX has moved today...up!
Probably the knock on effect .

joyjoy13
26/7/2017
08:06
Three product related r.n.s's in fifteen days and the next one could be the one with larger revenues attached. Multiple products times multiple partners could result in a revenue bearing r.n.s every week...the extra volume and new revenue feeds will take out the seller from lower levels. I just have to sit back and wait...
bobdown2
26/7/2017
07:53
Ohhhhh, come on!
I've only got one tick down...
I need two to be special...chuckle!

Go get a life....!

P.s. Got the biggest walnut tree in back garden...honestly!
( so that will have to do...)

joyjoy13
26/7/2017
07:48
Don't you just love these sellers :(
I hope and believe that one day they will rue their decision to sell
All these little deals are just that little deals. But out of small Acorns!!

judijudi
26/7/2017
07:28
Also add in the value of the outstanding IP and potential of sweet healthy sugars (which imho is mind blowing) then you can see why we are where we are currently! In fact I believe undervalued!
f3rdinand
26/7/2017
07:25
But the stock market values shares on future earnings and I think we can all see that (if all goes to plan) then OPTI will easily justify a £50 million mc! Having said that I understand your view and I expect many agree and will be waiting for a multi million deal before jumping on the train!
f3rdinand
26/7/2017
07:21
Since what's his face has altered his fellow traders again...
Well...
We will just have to wait and see if were traded again today but patience is a virtue
IMHO we will rocket one day and we can't be traded as the only way is up.

that's my thoughts on the matter but any newbie, please DYOR

joyjoy13
26/7/2017
07:18
I liked this sentence best

. We hope this will be the first of many product launches of multiple formulations and presentations of LPLDL® as the active component in a wide range of pharmaceutical and consumer products around the WORLD.

I quote
"WORLD"

Looking Ab Fab folks....
Well....we knew that anyway!

Any doubters now...
Well...
Be it on their own heads
I'm in OPTI and I'm chuffed to bits LTH

Good luck all

joyjoy13
26/7/2017
07:17
F3rdinand- If the current market cap was £5m rather than £50m I wouldn't bother since you're quite right commercialization is just starting but has yet to be proven.

I have no problem with the company just the current valuation.

Start-ups require fund raisings. Opti will need far more cash.

michaelmouse
26/7/2017
07:13
Your obsession with figures for a company that is literally just starting the commercialisation phase of their business is bizarre imho!
f3rdinand
26/7/2017
07:12
Perhaps they've made so much money they're still counting it out? ;)
michaelmouse
26/7/2017
06:59
Reduced to releasing old news now then. The smell of a fund raise is getting stronger by the day.

So that's just two deals announced fairly recently (including this mornings which has previously been released) that probably amounts to less than £500,000 for next year (if you're lucky). That's right 2018, and the market. cap is around £50m.

See post 1650.

Aimho of course.

michaelmouse
26/7/2017
06:52
Last post from me!Share Prophets on Twitter:Just posted: Optibiotix (#OPTI) starts German sales LPLDL - just look at sales forecasts! Game on! shareprophets.com/30550
parob
26/7/2017
06:47
IFA GMBHWe collect information about medicinal products and pharmacy typical products. These data are continuously kept up-to-date, the market participants technically supported in the performance of legal obligations and contribute to the optimization of logistics within the pharmaceutical distribution chain.We ensure the collection, processing and storage of data duly provided by the supplier, as well as the timely delivery of information services to eligible data users.PZN Pre-allocationWe assign PZN to medicinal products and other pharmacy typical products.The Bundesamt für Verbraucherschutz und Lebensmittelsicherheit ( BVL ) is a federal authority belonging to the business unit of the Federal Ministry of Food and Agriculture and headquartered in Braunschweig . It maintains a service in Berlin .
parob
26/7/2017
06:30
OK this isn't 'new' news to this bb (some here have already ordered the capsules!), but it's a way of alerting the wider market that we now have products containing our LP-LDL ingredient on the market (3 months after the initial agreement with HLH was announced) - and this will make other companies take note. We're looking at sales revenues of £200-500K in the near term and growing them. Lets remember sales will also generate revenue from our 50% manufacturing profit share with Sacco. I was hoping they'd RNS this launch.
parob
26/7/2017
06:28
This is just the start of revenues to Opti from such sales. How many other products will come to market that will bring revenue in? Hopefully, the market will start to realise how big Opti could be within a few years from now.
rafboy
26/7/2017
06:24
If we can hit mid six figure numbers for this launch then it won't take many more deals to start getting some serious revenue! In talks with 30 plus companies remember- some of which could be £5 million plus individually!
f3rdinand
26/7/2017
06:21
I also like the fact OPTI are listening to concerns RNSs are mostly predictably announced on Tuesdays.... Thus playing into traders strategy.
elrico
26/7/2017
06:18
The fact SOH is not attempting to use historical sales data for Lactobact® for the new higher cholesterol reduction version, demonstrates the integrity of the man. Many CEO's would have attempted to talk up sales expectation by using Lactobact® historical sales data.HLH clearly have a well established market and now with a jump from 12% claimed cholesterol reduction to a new improved rate of 36% reduction, HLH must be confident for the future sales performance.
elrico
26/7/2017
06:16
Promote them directly to the pharmacy market.......like that part!
bernieboy
26/7/2017
06:06
At last talk of revenues, not high but a start.
deeppockets
26/7/2017
06:04
OptiBiotix Health plc

("OptiBiotix" or the "Company")



Market launch for LPLDL® capsules in Germany



OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that HLH BioPharma Vertriebs GmbH ("HLH") have achieved product registration of LPLDL® capsules at IFA GmbH and "Bundesamt für Lebensmittelsicherheit und Verbraucherschutz (BVL)" and commenced commercial sales to pharmacies in Germany on 24 July 2017.



This announcement follows on from the three year supply agreement with HLH BioPharma Vertriebs GmbH ("HLH") announced on 15 June 2017. HLH will market capsules containing LPLDL® under the brand name Lactobact® LDL-Control and promote them directly to the pharmacy market in Germany, as well as to consumers on their online platform. Sales revenues are difficult to estimate in this new and developing market but are likely to be in the low to mid six figure in the near term growing as HLH builds market presence.



Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to see the first sales of our LPLDL® strain in products available to consumers in Germany. We hope this will be the first of many product launches of multiple formulations and presentations of LPLDL® as the active component in a wide range of pharmaceutical and consumer products around the world. HLH have an international reputation for providing high quality and scientifically validated products and are one of Europe's leading suppliers of probiotics to the pharmacy market. Establishing early sales of LPLDL® to pharmacies with HLH helps substantiate the credibility in the science behind LPLDL® to build the brand and acceptance in the larger consumer healthcare markets."

someuwin
26/7/2017
05:51
Thanks for the post shrewdie. Always good to hear from you and to know that you are still long and strong!
bernieboy
Chat Pages: Latest  1085  1084  1083  1082  1081  1080  1079  1078  1077  1076  1075  1074  Older

Your Recent History

Delayed Upgrade Clock